|
þ
|
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
|
o
|
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
|
Ohio
|
31-0958666
|
(State or other jurisdiction of
incorporation or organization)
|
(IRS Employer
Identification No.)
|
|
|
7000 Cardinal Place, Dublin, Ohio
|
43017
|
(Address of principal executive offices)
|
(Zip Code)
|
|
|
(614) 757-5000
|
|
(Registrant’s telephone number, including area code)
|
Large accelerated filer
þ
|
Accelerated filer
o
|
Non-accelerated filer
o
(Do not check if a smaller reporting company)
|
Smaller reporting company
o
|
Cardinal Health
Q2 Fiscal 2016 Form 10-Q
|
|
|
Page
|
|
|
|
1
|
Cardinal Health
|
Q2 Fiscal 2016 Form 10-Q
|
|
MD&A
|
|
|
|
|
Cardinal Health
|
Q2
Fiscal 2016 Form 10-Q
|
2
|
MD&A
|
Results of Operations
|
|
|
|
GAAP and Non-GAAP Operating Earnings
|
Three Months Ended December 31
|
|
Six Months Ended December 31
|
||||||||||||||||||
(in millions)
|
2015
|
|
2014
|
|
Change
|
|
2015
|
|
2014
|
|
Change
|
||||||||||
GAAP
|
$
|
563
|
|
|
$
|
546
|
|
|
3
|
%
|
|
$
|
1,183
|
|
|
$
|
1,012
|
|
|
17
|
%
|
LIFO charges/(credits)
|
39
|
|
|
—
|
|
|
|
|
39
|
|
|
—
|
|
|
|
||||||
Restructuring and employee severance
|
2
|
|
|
7
|
|
|
|
|
14
|
|
|
26
|
|
|
|
||||||
Amortization and other acquisition-related costs
|
114
|
|
|
60
|
|
|
|
|
219
|
|
|
112
|
|
|
|
||||||
Impairments and (gain)/loss on disposal of assets
|
17
|
|
|
(18
|
)
|
|
|
|
17
|
|
|
(18
|
)
|
|
|
||||||
Litigation (recoveries)/charges, net
|
(9
|
)
|
|
44
|
|
|
|
|
(9
|
)
|
|
72
|
|
|
|
||||||
Non-GAAP
|
$
|
726
|
|
|
$
|
639
|
|
|
14
|
%
|
|
$
|
1,463
|
|
|
$
|
1,204
|
|
|
22
|
%
|
3
|
Cardinal Health
|
Q2 Fiscal 2016 Form 10-Q
|
|
MD&A
|
Results of Operations
|
|
|
GAAP and Non-GAAP Diluted EPS
|
Three Months Ended December 31
|
|
Six Months Ended December 31
|
||||||||||||||||||
|
2015
|
|
2014
|
|
Change
|
|
2015
|
|
2014
|
|
Change
|
||||||||||
GAAP
|
$
|
0.98
|
|
|
$
|
0.86
|
|
|
14
|
%
|
|
$
|
2.14
|
|
|
$
|
1.65
|
|
|
30
|
%
|
LIFO charges/(credits)
|
0.07
|
|
|
—
|
|
|
|
|
0.07
|
|
|
—
|
|
|
|
||||||
Restructuring and employee severance
|
—
|
|
|
0.01
|
|
|
|
|
0.02
|
|
|
0.05
|
|
|
|
||||||
Amortization and other acquisition-related costs
|
0.22
|
|
|
0.11
|
|
|
|
|
0.42
|
|
|
0.21
|
|
|
|
||||||
Impairments and (gain)/loss on disposal of assets
|
0.03
|
|
|
(0.03
|
)
|
|
|
|
0.03
|
|
|
(0.02
|
)
|
|
|
||||||
Litigation (recoveries)/charges, net
|
(0.01
|
)
|
|
0.12
|
|
|
|
|
(0.01
|
)
|
|
0.20
|
|
|
|
||||||
Loss on extinguishment of debt
|
—
|
|
|
0.11
|
|
|
|
|
—
|
|
|
0.11
|
|
|
|
||||||
Non-GAAP
|
$
|
1.30
|
|
|
$
|
1.20
|
|
|
8
|
%
|
|
$
|
2.68
|
|
|
$
|
2.19
|
|
|
22
|
%
|
|
|
Cardinal Health
|
Q2
Fiscal 2016 Form 10-Q
|
4
|
MD&A
|
Results of Operations
|
|
|
|
Three Months Ended December 31
|
|
Six Months Ended December 31
|
||||||||||||||||||
(in millions)
|
2015
|
|
2014
|
|
Change
|
|
2015
|
|
2014
|
|
Change
|
||||||||||
Pharmaceutical
|
$
|
28,287
|
|
|
$
|
22,627
|
|
|
25
|
%
|
|
$
|
53,427
|
|
|
$
|
43,836
|
|
|
22
|
%
|
Medical
|
3,162
|
|
|
2,914
|
|
|
9
|
%
|
|
6,081
|
|
|
5,766
|
|
|
5
|
%
|
||||
Total segment revenue
|
31,449
|
|
|
25,541
|
|
|
23
|
%
|
|
59,508
|
|
|
49,602
|
|
|
20
|
%
|
||||
Corporate
|
(4
|
)
|
|
(4
|
)
|
|
N.M.
|
|
|
(9
|
)
|
|
5
|
|
|
N.M.
|
|
||||
Total revenue
|
$
|
31,445
|
|
|
$
|
25,537
|
|
|
23
|
%
|
|
$
|
59,499
|
|
|
$
|
49,607
|
|
|
20
|
%
|
|
|
|
5
|
Cardinal Health
|
Q2 Fiscal 2016 Form 10-Q
|
|
MD&A
|
Results of Operations
|
|
|
|
Three Months Ended December 31
|
|
Six Months Ended December 31
|
||||||||||||||||||
(in millions)
|
2015
|
|
2014
|
|
Change
|
|
2015
|
|
2014
|
|
Change
|
||||||||||
Gross margin
|
$
|
1,609
|
|
|
$
|
1,454
|
|
|
11
|
%
|
|
$
|
3,188
|
|
|
$
|
2,794
|
|
|
14
|
%
|
|
|
Three Months Ended December 31
|
|
Six Months Ended December 31
|
||||||||||||||||||
(in millions)
|
2015
|
|
2014
|
|
Change
|
|
2015
|
|
2014
|
|
Change
|
||||||||||
SG&A expenses
|
$
|
922
|
|
|
$
|
815
|
|
|
13
|
%
|
|
$
|
1,764
|
|
|
$
|
1,590
|
|
|
11
|
%
|
|
Cardinal Health
|
Q2
Fiscal 2016 Form 10-Q
|
6
|
MD&A
|
Results of Operations
|
|
|
|
Three Months Ended December 31
|
|
Six Months Ended December 31
|
||||||||||||||||||
(in millions)
|
2015
|
|
2014
|
|
Change
|
|
2015
|
|
2014
|
|
Change
|
||||||||||
Pharmaceutical
|
$
|
627
|
|
|
$
|
542
|
|
|
16
|
%
|
|
$
|
1,285
|
|
|
$
|
992
|
|
|
29
|
%
|
Medical
|
106
|
|
|
115
|
|
|
(8
|
)%
|
|
207
|
|
|
229
|
|
|
(10
|
)%
|
||||
Total segment profit
|
733
|
|
|
657
|
|
|
12
|
%
|
|
1,492
|
|
|
1,221
|
|
|
22
|
%
|
||||
Corporate
|
(170
|
)
|
|
(111
|
)
|
|
N.M.
|
|
|
(309
|
)
|
|
(209
|
)
|
|
N.M.
|
|
||||
Total consolidated operating earnings
|
$
|
563
|
|
|
$
|
546
|
|
|
3
|
%
|
|
$
|
1,183
|
|
|
$
|
1,012
|
|
|
17
|
%
|
7
|
Cardinal Health
|
Q2 Fiscal 2016 Form 10-Q
|
|
MD&A
|
Results of Operations
|
|
|
|
Three Months Ended December 31
|
|
Six Months Ended December 31
|
||||||||||||
(in millions)
|
2015
|
|
2014
|
|
2015
|
|
2014
|
||||||||
Restructuring and employee severance
|
$
|
2
|
|
|
$
|
7
|
|
|
$
|
14
|
|
|
$
|
26
|
|
Amortization and other acquisition-related costs
|
114
|
|
|
60
|
|
|
219
|
|
|
112
|
|
||||
Impairments and (gain)/loss on disposal of assets, net
|
17
|
|
|
(18
|
)
|
|
17
|
|
|
(18
|
)
|
||||
Litigation (recoveries)/charges, net
|
(9
|
)
|
|
44
|
|
|
(9
|
)
|
|
72
|
|
|
|
Three Months Ended December 31
|
|
Six Months Ended December 31
|
||||||||||||||||||
(in millions)
|
2015
|
|
2014
|
|
Change
|
|
2015
|
|
2014
|
|
Change
|
||||||||||
Other (income)/expense, net
|
$
|
(2
|
)
|
|
$
|
(1
|
)
|
|
N.M.
|
|
|
$
|
6
|
|
|
$
|
(4
|
)
|
|
N.M.
|
|
Interest expense, net
|
45
|
|
|
36
|
|
|
24
|
%
|
|
90
|
|
|
70
|
|
|
28
|
%
|
||||
Loss on extinguishment of debt
|
—
|
|
|
60
|
|
|
N.M.
|
|
|
—
|
|
|
60
|
|
|
N.M.
|
|
|
|
Cardinal Health
|
Q2
Fiscal 2016 Form 10-Q
|
8
|
MD&A
|
Liquidity and Capital Resources
|
|
|
|
|
9
|
Cardinal Health
|
Q2 Fiscal 2016 Form 10-Q
|
|
MD&A
|
Other
|
|
|
Cardinal Health
|
Q2
Fiscal 2016 Form 10-Q
|
10
|
Explanation and Reconciliation of Non-GAAP Financial Measures
|
|
|
11
|
Cardinal Health
|
Q2 Fiscal 2016 Form 10-Q
|
|
MD&A
|
|
|
|
|
|
|
Net Earnings
|
|
Diluted EPS
|
|||||||||
|
|
|
Net Earnings
|
attributable
|
Diluted EPS
|
attributable
|
|||||||||
|
|
Operating
|
attributable
|
to Cardinal
|
attributable
|
to Cardinal
|
|||||||||
|
Operating
|
Earnings
|
to Cardinal
|
Health, Inc.
|
to Cardinal
|
Health, Inc.
|
|||||||||
Earnings
|
Growth Rate
|
Health, Inc.
|
Growth Rate
|
Health, Inc.
|
Growth Rate
|
||||||||||
(in millions, except per common share amounts)
|
Three Months Ended December 31, 2015
|
||||||||||||||
GAAP
|
$
|
563
|
|
3
|
%
|
$
|
326
|
|
13
|
%
|
$
|
0.98
|
|
14
|
%
|
LIFO charges/(credits)
|
39
|
|
|
24
|
|
|
0.07
|
|
|
||||||
Restructuring and employee severance
|
2
|
|
|
1
|
|
|
—
|
|
|
||||||
Amortization and other acquisition-related costs
|
114
|
|
|
73
|
|
|
0.22
|
|
|
||||||
Impairments and (gain)/loss on disposal of assets
|
17
|
|
|
10
|
|
|
0.03
|
|
|
||||||
Litigation (recoveries)/charges, net
|
(9
|
)
|
|
(4
|
)
|
|
(0.01
|
)
|
|
||||||
Non-GAAP
|
$
|
726
|
|
14
|
%
|
$
|
430
|
|
7
|
%
|
$
|
1.30
|
|
8
|
%
|
|
|
|
|
|
|
|
|||||||||
|
Three Months Ended December 31, 2014
|
||||||||||||||
GAAP
|
$
|
546
|
|
5
|
%
|
$
|
289
|
|
5
|
%
|
$
|
0.86
|
|
9
|
%
|
Restructuring and employee severance
|
7
|
|
|
4
|
|
|
0.01
|
|
|
||||||
Amortization and other acquisition-related costs
|
60
|
|
|
38
|
|
|
0.11
|
|
|
||||||
Impairments and (gain)/loss on disposal of assets
|
(18
|
)
|
|
(8
|
)
|
|
(0.03
|
)
|
|
||||||
Litigation (recoveries)/charges, net
|
44
|
|
|
40
|
|
|
0.12
|
|
|
||||||
Loss on extinguishment of debt
|
—
|
|
|
37
|
|
|
0.11
|
|
|
||||||
Non-GAAP
|
$
|
639
|
|
10
|
%
|
$
|
400
|
|
28
|
%
|
$
|
1.20
|
|
33
|
%
|
|
|
|
|
|
|
|
|||||||||
|
Six Months Ended December 31, 2015
|
||||||||||||||
GAAP
|
$
|
1,183
|
|
17
|
%
|
$
|
709
|
|
28
|
%
|
$
|
2.14
|
|
30
|
%
|
LIFO charges/(credits)
|
39
|
|
|
24
|
|
|
0.07
|
|
|
||||||
Restructuring and employee severance
|
14
|
|
|
9
|
|
|
0.02
|
|
|
||||||
Amortization and other acquisition-related costs
|
219
|
|
|
141
|
|
|
0.42
|
|
|
||||||
Impairments and (gain)/loss on disposal of assets
|
17
|
|
|
10
|
|
|
0.03
|
|
|
||||||
Litigation (recoveries)/charges, net
|
(9
|
)
|
|
(4
|
)
|
|
(0.01
|
)
|
|
||||||
Non-GAAP
|
$
|
1,463
|
|
22
|
%
|
$
|
889
|
|
20
|
%
|
$
|
2.68
|
|
22
|
%
|
|
|
|
|
|
|
|
|||||||||
|
Six Months Ended December 31, 2014
|
||||||||||||||
GAAP
|
$
|
1,012
|
|
2
|
%
|
$
|
555
|
|
(10
|
)%
|
$
|
1.65
|
|
(7
|
)%
|
Restructuring and employee severance
|
26
|
|
|
17
|
|
|
0.05
|
|
|
||||||
Amortization and other acquisition-related costs
|
112
|
|
|
71
|
|
|
0.21
|
|
|
||||||
Impairments and (gain)/loss on disposal of assets
|
(18
|
)
|
|
(8
|
)
|
|
(0.02
|
)
|
|
||||||
Litigation (recoveries)/charges, net
|
72
|
|
|
68
|
|
|
0.20
|
|
|
||||||
Loss on extinguishment of debt
|
—
|
|
|
37
|
|
|
0.11
|
|
|
||||||
Non-GAAP
|
$
|
1,204
|
|
8
|
%
|
$
|
740
|
|
7
|
%
|
$
|
2.19
|
|
10
|
%
|
|
Cardinal Health
|
Q2
Fiscal 2016 Form 10-Q
|
12
|
Other
|
|
|
Period
|
Total Number
of Shares Purchased (1) |
|
Average Price Paid per Share
|
|
Total Number of Shares
Purchased as Part of Publicly Announced Program (2) |
|
Approximate
Dollar Value of
Shares That May
Yet be Purchased
Under the Program (2)
(in millions)
|
||||||
October 2015
|
266
|
|
|
$
|
79.88
|
|
|
—
|
|
|
$
|
693
|
|
November 2015
|
231
|
|
|
87.72
|
|
|
—
|
|
|
693
|
|
||
December 2015
|
221
|
|
|
88.83
|
|
|
—
|
|
|
693
|
|
||
Total
|
718
|
|
|
$
|
85.16
|
|
|
—
|
|
|
$
|
693
|
|
(1)
|
Common shares purchased through a rabbi trust as investments of participants in our Deferred Compensation Plan.
|
(2)
|
On October 29, 2013, our Board of Directors approved a $1.0 billion share repurchase program and on August 6, 2014, the Board of Directors authorized an additional $1.0 billion under the program, for a total of $2.0 billion. This program expires on December 31, 2016. We did not repurchase common shares under this program during the three months ended
December 31, 2015
.
|
13
|
Cardinal Health
|
Q2 Fiscal 2016 Form 10-Q
|
|
Financial Statements
|
|
|
|
Three Months Ended December 31
|
|
Six Months Ended December 31
|
||||||||||||
(in millions, except per common share amounts)
|
2015
|
|
2014
|
|
2015
|
|
2014
|
||||||||
Revenue
|
$
|
31,445
|
|
|
$
|
25,537
|
|
|
$
|
59,499
|
|
|
$
|
49,607
|
|
Cost of products sold
|
29,836
|
|
|
24,083
|
|
|
56,311
|
|
|
46,813
|
|
||||
Gross margin
|
1,609
|
|
|
1,454
|
|
|
3,188
|
|
|
2,794
|
|
||||
|
|
|
|
|
|
|
|
||||||||
Operating expenses:
|
|
|
|
|
|
|
|
||||||||
Distribution, selling, general, and administrative expenses
|
922
|
|
|
815
|
|
|
1,764
|
|
|
1,590
|
|
||||
Restructuring and employee severance
|
2
|
|
|
7
|
|
|
14
|
|
|
26
|
|
||||
Amortization and other acquisition-related costs
|
114
|
|
|
60
|
|
|
219
|
|
|
112
|
|
||||
Impairments and (gain)/loss on disposal of assets, net
|
17
|
|
|
(18
|
)
|
|
17
|
|
|
(18
|
)
|
||||
Litigation (recoveries)/charges, net
|
(9
|
)
|
|
44
|
|
|
(9
|
)
|
|
72
|
|
||||
Operating earnings
|
563
|
|
|
546
|
|
|
1,183
|
|
|
1,012
|
|
||||
|
|
|
|
|
|
|
|
||||||||
Other (income)/expense, net
|
(2
|
)
|
|
(1
|
)
|
|
6
|
|
|
(4
|
)
|
||||
Interest expense, net
|
45
|
|
|
36
|
|
|
90
|
|
|
70
|
|
||||
Loss on extinguishment of debt
|
—
|
|
|
60
|
|
|
—
|
|
|
60
|
|
||||
Earnings before income taxes
|
520
|
|
|
451
|
|
|
1,087
|
|
|
886
|
|
||||
|
|
|
|
|
|
|
|
||||||||
Provision for income taxes
|
194
|
|
|
162
|
|
|
377
|
|
|
331
|
|
||||
Net earnings
|
326
|
|
|
289
|
|
|
710
|
|
|
555
|
|
||||
|
|
|
|
|
|
|
|
||||||||
Less: Net earnings attributable to noncontrolling interests
|
—
|
|
|
—
|
|
|
(1
|
)
|
|
—
|
|
||||
Net earnings attributable to Cardinal Health, Inc.
|
$
|
326
|
|
|
$
|
289
|
|
|
$
|
709
|
|
|
$
|
555
|
|
|
|
|
|
|
|
|
|
||||||||
Earnings per common share attributable to Cardinal Health, Inc.:
|
|
|
|
|
|
|
|
||||||||
Basic
|
$
|
0.99
|
|
|
$
|
0.87
|
|
|
$
|
2.16
|
|
|
$
|
1.66
|
|
Diluted
|
0.98
|
|
|
0.86
|
|
|
2.14
|
|
|
1.65
|
|
||||
|
|
|
|
|
|
|
|
||||||||
Weighted-average number of common shares outstanding:
|
|
|
|
|
|
|
|
||||||||
Basic
|
329
|
|
|
331
|
|
|
329
|
|
|
333
|
|
||||
Diluted
|
332
|
|
|
334
|
|
|
332
|
|
|
337
|
|
||||
|
|
|
|
|
|
|
|
||||||||
Cash dividends declared per common share
|
$
|
0.3870
|
|
|
$
|
0.3425
|
|
|
$
|
0.7740
|
|
|
$
|
0.6850
|
|
|
Cardinal Health
|
Q2
Fiscal 2016 Form 10-Q
|
14
|
Financial Statements
|
|
|
|
Three Months Ended December 31
|
|
Six Months Ended December 31
|
||||||||||||
(in millions)
|
2015
|
|
2014
|
|
2015
|
|
2014
|
||||||||
Net earnings
|
$
|
326
|
|
|
$
|
289
|
|
|
$
|
710
|
|
|
$
|
555
|
|
|
|
|
|
|
|
|
|
||||||||
Other comprehensive loss:
|
|
|
|
|
|
|
|
||||||||
Foreign currency translation adjustments
|
(28
|
)
|
|
(40
|
)
|
|
(73
|
)
|
|
(64
|
)
|
||||
Net unrealized loss on derivative instruments, net of tax
|
(1
|
)
|
|
(9
|
)
|
|
(1
|
)
|
|
(9
|
)
|
||||
Total other comprehensive loss, net of tax
|
(29
|
)
|
|
(49
|
)
|
|
(74
|
)
|
|
(73
|
)
|
||||
|
|
|
|
|
|
|
|
||||||||
Total comprehensive income
|
297
|
|
|
240
|
|
|
636
|
|
|
482
|
|
||||
|
|
|
|
|
|
|
|
||||||||
Less: Comprehensive income attributable to noncontrolling interests
|
—
|
|
|
—
|
|
|
(1
|
)
|
|
—
|
|
||||
Total comprehensive income attributable to Cardinal Health, Inc.
|
$
|
297
|
|
|
$
|
240
|
|
|
$
|
635
|
|
|
$
|
482
|
|
15
|
Cardinal Health
|
Q2 Fiscal 2016 Form 10-Q
|
|
Financial Statements
|
|
|
(in millions)
|
December 31, 2015
|
|
June 30,
2015 |
||||
|
(Unaudited)
|
|
|
||||
Assets
|
|
|
|
||||
Current assets:
|
|
|
|
||||
Cash and equivalents
|
$
|
2,324
|
|
|
$
|
4,616
|
|
Trade receivables, net
|
6,980
|
|
|
6,523
|
|
||
Inventories, net
|
11,007
|
|
|
9,211
|
|
||
Prepaid expenses and other
|
1,518
|
|
|
1,402
|
|
||
Total current assets
|
21,829
|
|
|
21,752
|
|
||
|
|
|
|
||||
Property and equipment, net
|
1,651
|
|
|
1,506
|
|
||
Goodwill and other intangibles, net
|
9,113
|
|
|
6,018
|
|
||
Other assets
|
914
|
|
|
866
|
|
||
Total assets
|
$
|
33,507
|
|
|
$
|
30,142
|
|
|
|
|
|
||||
Liabilities, Redeemable Noncontrolling Interests, and Shareholders’ Equity
|
|
|
|
||||
Current liabilities:
|
|
|
|
||||
Accounts payable
|
$
|
16,919
|
|
|
$
|
14,368
|
|
Current portion of long-term obligations and other short-term borrowings
|
354
|
|
|
281
|
|
||
Other accrued liabilities
|
1,606
|
|
|
2,594
|
|
||
Total current liabilities
|
18,879
|
|
|
17,243
|
|
||
|
|
|
|
||||
Long-term obligations, less current portion
|
5,171
|
|
|
5,211
|
|
||
Deferred income taxes and other liabilities
|
2,609
|
|
|
1,432
|
|
||
|
|
|
|
||||
Redeemable noncontrolling interests
|
120
|
|
|
—
|
|
||
|
|
|
|
||||
Shareholders’ equity:
|
|
|
|
||||
Preferred shares, without par value:
|
|
|
|
||||
Authorized—
500 thousand
shares, Issued—
none
|
—
|
|
|
—
|
|
||
Common shares, without par value:
|
|
|
|
||||
Authorized—
755 million
shares, Issued—
364
million
shares at
December 31, 2015
and June 30, 2015
|
2,973
|
|
|
3,003
|
|
||
Retained earnings
|
5,972
|
|
|
5,521
|
|
||
Common shares in treasury, at cost:
34 million
shares and 36 million shares at
December 31, 2015
and June 30, 2015, respectively
|
(2,137
|
)
|
|
(2,245
|
)
|
||
Accumulated other comprehensive loss
|
(97
|
)
|
|
(23
|
)
|
||
Total Cardinal Health, Inc. shareholders' equity
|
6,711
|
|
|
6,256
|
|
||
Noncontrolling interests
|
17
|
|
|
—
|
|
||
Total shareholders’ equity
|
6,728
|
|
|
6,256
|
|
||
Total liabilities, redeemable noncontrolling interests, and shareholders’ equity
|
$
|
33,507
|
|
|
$
|
30,142
|
|
|
Cardinal Health
|
Q2
Fiscal 2016 Form 10-Q
|
16
|
Financial Statements
|
|
|
|
Six Months Ended December 31
|
||||||
(in millions)
|
2015
|
|
2014
|
||||
Cash flows from operating activities:
|
|
|
|
||||
Net earnings
|
$
|
710
|
|
|
$
|
555
|
|
|
|
|
|
||||
Adjustments to reconcile net earnings to net cash provided by operating activities:
|
|
|
|
||||
Depreciation and amortization
|
306
|
|
|
220
|
|
||
Loss on extinguishment of debt
|
—
|
|
|
60
|
|
||
Gain on sale of other investments
|
—
|
|
|
(5
|
)
|
||
Impairments and (gain)/loss on disposal of assets, net
|
17
|
|
|
(18
|
)
|
||
Share-based compensation
|
56
|
|
|
53
|
|
||
Provision for bad debts
|
35
|
|
|
26
|
|
||
Change in fair value of contingent consideration obligation
|
(14
|
)
|
|
—
|
|
||
Change in operating assets and liabilities, net of effects from acquisitions:
|
|
|
|
||||
Increase in trade receivables
|
(393
|
)
|
|
(291
|
)
|
||
Increase in inventories
|
(1,565
|
)
|
|
(1,137
|
)
|
||
Increase in accounts payable
|
2,431
|
|
|
1,438
|
|
||
Other accrued liabilities and operating items, net
|
(172
|
)
|
|
113
|
|
||
Net cash provided by operating activities
|
1,411
|
|
|
1,014
|
|
||
|
|
|
|
||||
Cash flows from investing activities:
|
|
|
|
||||
Acquisition of subsidiaries, net of cash acquired
|
(3,284
|
)
|
|
(86
|
)
|
||
Additions to property and equipment
|
(175
|
)
|
|
(83
|
)
|
||
Purchase of available-for-sale securities and other investments
|
(88
|
)
|
|
(107
|
)
|
||
Proceeds from sale of available-for-sale securities and other investments
|
57
|
|
|
107
|
|
||
Proceeds from maturities of available-for-sale securities
|
19
|
|
|
16
|
|
||
Proceeds from divestitures and disposal of held for sale assets
|
—
|
|
|
53
|
|
||
Net cash used in investing activities
|
(3,471
|
)
|
|
(100
|
)
|
||
|
|
|
|
||||
Cash flows from financing activities:
|
|
|
|
||||
Payment of contingent consideration obligation
|
(23
|
)
|
|
—
|
|
||
Net change in short-term borrowings
|
39
|
|
|
(18
|
)
|
||
Reduction of long-term obligations
|
(4
|
)
|
|
(1,220
|
)
|
||
Proceeds from long-term obligations, net of issuance costs
|
—
|
|
|
1,182
|
|
||
Net proceeds/(tax withholdings) from share-based compensation
|
(7
|
)
|
|
35
|
|
||
Tax proceeds from share-based compensation
|
32
|
|
|
42
|
|
||
Dividends on common shares
|
(259
|
)
|
|
(233
|
)
|
||
Purchase of treasury shares
|
—
|
|
|
(686
|
)
|
||
Net cash used in financing activities
|
(222
|
)
|
|
(898
|
)
|
||
|
|
|
|
||||
Effect of exchange rate changes on cash and equivalents
|
(10
|
)
|
|
—
|
|
||
|
|
|
|
||||
Net increase/(decrease) in cash and equivalents
|
(2,292
|
)
|
|
16
|
|
||
Cash and equivalents at beginning of period
|
4,616
|
|
|
2,865
|
|
||
Cash and equivalents at end of period
|
$
|
2,324
|
|
|
$
|
2,881
|
|
17
|
Cardinal Health
|
Q2 Fiscal 2016 Form 10-Q
|
|
Notes to Financial Statements
|
|
|
|
Cardinal Health
|
Q2
Fiscal 2016 Form 10-Q
|
18
|
Notes to Financial Statements
|
|
|
19
|
Cardinal Health
|
Q2 Fiscal 2016 Form 10-Q
|
|
Notes to Financial Statements
|
|
|
(in millions)
|
Cordis
|
|
naviHealth
|
|
Harvard Drug
|
||||||
Identifiable intangible assets:
|
|
|
|
|
|
||||||
Customer relationships (1)
|
$
|
230
|
|
|
$
|
38
|
|
|
$
|
470
|
|
Trade names (2)
|
130
|
|
|
16
|
|
|
130
|
|
|||
Developed technology (3)
|
400
|
|
|
61
|
|
|
—
|
|
|||
In-process research and development (4)
|
55
|
|
|
—
|
|
|
—
|
|
|||
Total identifiable intangible assets acquired
|
815
|
|
|
115
|
|
|
600
|
|
|||
|
|
|
|
|
|
||||||
Cash and equivalents
|
—
|
|
|
53
|
|
|
46
|
|
|||
Trade receivables
|
—
|
|
|
38
|
|
|
67
|
|
|||
Inventories
|
213
|
|
|
—
|
|
|
49
|
|
|||
Prepaid expenses and other
|
4
|
|
|
14
|
|
|
12
|
|
|||
Property and equipment
|
98
|
|
|
5
|
|
|
16
|
|
|||
Other assets
|
10
|
|
|
1
|
|
|
1
|
|
|||
Accounts payable
|
(81
|
)
|
|
(2
|
)
|
|
(48
|
)
|
|||
Other accrued liabilities
|
(11
|
)
|
|
(95
|
)
|
|
(39
|
)
|
|||
Deferred income taxes and other liabilities
|
(7
|
)
|
|
(42
|
)
|
|
(104
|
)
|
|||
Redeemable noncontrolling interests
|
—
|
|
|
(119
|
)
|
|
—
|
|
|||
Total identifiable net assets/(liabilities) acquired
|
1,041
|
|
|
(32
|
)
|
|
600
|
|
|||
Goodwill
|
832
|
|
|
323
|
|
|
551
|
|
|||
Total net assets acquired
|
$
|
1,873
|
|
|
$
|
291
|
|
|
$
|
1,151
|
|
(1)
|
The weighted-average useful lives of customer relationships range from
4
to
13
years.
|
(2)
|
The weighted-average useful lives of trade names range from
10
to
17
years.
|
(3)
|
The weighted-average useful life of developed technology is
10
years.
|
(4)
|
Acquired in-process research and development ("IPR&D") intangible assets have an indefinite-life.
|
|
Three Months Ended December 31
|
||||||
(in millions)
|
2015
|
|
2014
|
||||
Employee-related costs (1)
|
$
|
—
|
|
|
$
|
5
|
|
Facility exit and other costs (2)
|
2
|
|
|
2
|
|
||
Total restructuring and employee severance
|
$
|
2
|
|
|
$
|
7
|
|
|
Six Months Ended December 31
|
||||||
(in millions)
|
2015
|
|
2014
|
||||
Employee-related costs (1)
|
$
|
6
|
|
|
$
|
21
|
|
Facility exit and other costs (2)
|
8
|
|
|
5
|
|
||
Total restructuring and employee severance
|
$
|
14
|
|
|
$
|
26
|
|
(1)
|
Employee-related costs primarily consist of termination benefits provided to employees who have been involuntarily terminated and duplicate payroll costs
|
(2)
|
Facility exit and other costs primarily consist of lease termination costs, accelerated depreciation, equipment relocation costs, project consulting fees, and costs associated with restructuring our delivery of information technology infrastructure services.
|
(in millions)
|
Employee-
Related Costs
|
|
Facility Exit
and Other Costs
|
|
Total
|
||||||
Balance at June 30, 2015
|
$
|
22
|
|
|
$
|
—
|
|
|
$
|
22
|
|
Additions
|
7
|
|
|
2
|
|
|
9
|
|
|||
Payments and other adjustments
|
(13
|
)
|
|
—
|
|
|
(13
|
)
|
|||
Balance at December 31, 2015
|
$
|
16
|
|
|
$
|
2
|
|
|
$
|
18
|
|
(in millions)
|
Pharmaceutical
|
|
Medical
|
|
Total
|
||||||
Balance at June 30, 2015
|
$
|
2,199
|
|
|
$
|
2,871
|
|
|
$
|
5,070
|
|
Goodwill acquired, net of purchase price adjustments
|
578
|
|
|
1,178
|
|
|
1,756
|
|
|||
Foreign currency translation adjustments and other
|
(13
|
)
|
|
(14
|
)
|
|
(27
|
)
|
|||
Balance at December 31, 2015
|
$
|
2,764
|
|
|
$
|
4,035
|
|
|
$
|
6,799
|
|
|
Cardinal Health
|
Q2
Fiscal 2016 Form 10-Q
|
20
|
Notes to Financial Statements
|
|
|
|
December 31, 2015
|
||||||||||||
(in millions)
|
Gross
Intangible
|
|
Accumulated
Amortization
|
|
Net
Intangible
|
|
Weighted Average Remaining Amortization Period (Years)
|
||||||
Indefinite-life intangibles:
|
|
|
|
|
|
|
|
||||||
IPR&D, trademarks and other
|
$
|
69
|
|
|
$
|
—
|
|
|
$
|
69
|
|
|
N/A
|
Total indefinite-life intangibles
|
69
|
|
|
—
|
|
|
69
|
|
|
N/A
|
|||
|
|
|
|
|
|
|
|
||||||
Definite-life intangibles:
|
|
|
|
|
|
|
|
||||||
Customer relationships
|
1,826
|
|
|
620
|
|
|
1,206
|
|
|
10
|
|||
Trademarks, trade names, and patents
|
512
|
|
|
112
|
|
|
400
|
|
|
15
|
|||
Developed technology and other
|
793
|
|
|
154
|
|
|
639
|
|
|
10
|
|||
Total definite-life intangibles
|
3,131
|
|
|
886
|
|
|
2,245
|
|
|
11
|
|||
Total other intangible assets
|
$
|
3,200
|
|
|
$
|
886
|
|
|
$
|
2,314
|
|
|
N/A
|
|
June 30, 2015
|
||||||||||
(in millions)
|
Gross
Intangible
|
|
Accumulated
Amortization
|
|
Net
Intangible
|
||||||
Indefinite-life intangibles:
|
|
|
|
|
|
||||||
Trademarks and other
|
$
|
14
|
|
|
$
|
—
|
|
|
$
|
14
|
|
Total indefinite-life intangibles
|
14
|
|
|
—
|
|
|
14
|
|
|||
|
|
|
|
|
|
||||||
Definite-life intangibles:
|
|
|
|
|
|
||||||
Customer relationships
|
1,103
|
|
|
501
|
|
|
602
|
|
|||
Trademarks, trade names, and patents
|
237
|
|
|
91
|
|
|
146
|
|
|||
Developed technology and other
|
320
|
|
|
134
|
|
|
186
|
|
|||
Total definite-life intangibles
|
1,660
|
|
|
726
|
|
|
934
|
|
|||
Total other intangible assets
|
$
|
1,674
|
|
|
$
|
726
|
|
|
$
|
948
|
|
(in millions)
|
December 31, 2015
|
|
June 30, 2015
|
||||
Current available-for-sale securities:
|
|
|
|
||||
Commercial paper
|
$
|
2
|
|
|
$
|
4
|
|
Treasury bills
|
2
|
|
|
12
|
|
||
International bonds
|
—
|
|
|
2
|
|
||
Corporate bonds
|
53
|
|
|
34
|
|
||
U.S. agency bonds
|
1
|
|
|
5
|
|
||
Asset-backed securities
|
28
|
|
|
8
|
|
||
International equity securities
|
2
|
|
|
—
|
|
||
U.S. agency mortgage-backed securities
|
16
|
|
|
26
|
|
||
Total current available-for-sale securities
|
104
|
|
|
91
|
|
||
|
|
|
|
||||
Long-term available-for-sale securities:
|
|
|
|
||||
International bonds
|
1
|
|
|
—
|
|
||
Corporate bonds
|
29
|
|
|
33
|
|
||
U.S. agency bonds
|
31
|
|
|
18
|
|
||
Asset-backed securities
|
20
|
|
|
41
|
|
||
U.S. agency mortgage-backed securities
|
13
|
|
|
10
|
|
||
Total long-term available-for-sale securities
|
94
|
|
|
102
|
|
||
Total available-for-sale securities
|
$
|
198
|
|
|
$
|
193
|
|
21
|
Cardinal Health
|
Q2 Fiscal 2016 Form 10-Q
|
|
Notes to Financial Statements
|
|
|
|
Cardinal Health
|
Q2
Fiscal 2016 Form 10-Q
|
22
|
Notes to Financial Statements
|
|
|
|
December 31, 2015
|
||||||||||||||
(in millions)
|
Level 1
|
|
Level 2
|
|
Level 3
|
|
Total
|
||||||||
Assets:
|
|
|
|
|
|
|
|
||||||||
Cash equivalents (1)
|
$
|
554
|
|
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
554
|
|
Forward contracts (2)
|
—
|
|
|
5
|
|
|
—
|
|
|
5
|
|
||||
Available-for-sale securities (3)
|
—
|
|
|
198
|
|
|
—
|
|
|
198
|
|
||||
Other investments (4)
|
115
|
|
|
—
|
|
|
—
|
|
|
115
|
|
||||
Liabilities:
|
|
|
|
|
|
|
|
||||||||
Contingent Consideration (5)
|
—
|
|
|
—
|
|
|
(23
|
)
|
|
(23
|
)
|
|
June 30, 2015
|
||||||||||||||
(in millions)
|
Level 1
|
|
Level 2
|
|
Level 3
|
|
Total
|
||||||||
Assets:
|
|
|
|
|
|
|
|
||||||||
Cash equivalents (1)
|
$
|
1,809
|
|
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
1,809
|
|
Forward contracts (2)
|
—
|
|
|
5
|
|
|
—
|
|
|
5
|
|
||||
Available-for-sale securities (3)
|
—
|
|
|
193
|
|
|
—
|
|
|
193
|
|
||||
Other investments (4)
|
111
|
|
|
—
|
|
|
—
|
|
|
111
|
|
||||
Liabilities:
|
|
|
|
|
|
|
|
||||||||
Contingent Consideration (5)
|
—
|
|
|
—
|
|
|
(53
|
)
|
|
(53
|
)
|
(1)
|
Cash equivalents are comprised of highly liquid investments purchased with a maturity of three months or less. The carrying value of these cash equivalents approximates fair value due to their short-term maturities.
|
(2)
|
The fair value of interest rate swaps, foreign currency contracts, and commodity contracts is determined based on the present value of expected future cash flows considering the risks involved, including non-performance risk, and using discount rates appropriate for the respective maturities. Observable Level 2 inputs are used to determine the present value of expected future cash flows. The fair value of these derivative contracts, which are subject to master netting arrangements under certain circumstances, is presented on a gross basis in the condensed consolidated balance sheets.
|
(3)
|
We invest in marketable securities, which are classified as available-for-sale and are carried at fair value in the condensed consolidated balance sheets.
|
(4)
|
The other investments balance includes investments in mutual funds, which are used to offset fluctuations in deferred compensation liabilities. These mutual funds primarily invest in the equity securities of companies with large market capitalization and high quality fixed income debt securities. The fair value of these investments is determined using quoted market prices.
|
(5)
|
Contingent consideration represents the obligations incurred in connection with acquisitions. We do not deem the fair value of the contingent consideration obligations under any single acquisition to be significant. The estimate of fair value of the contingent consideration obligations requires subjective assumptions to be made regarding future business results, discount rates, discount periods, and probabilities assigned to various potential business result scenarios and was determined using probability assessments with respect to the likelihood of reaching various targets or from achieving certain milestones. The fair value measurement is based on significant inputs unobservable in the market and thus represents a Level 3 measurement. Failure to meet current expectations of progress could increase the probability of not achieving the targets within the measurement periods and result in a reduction in the fair value of the contingent consideration obligation.
|
(in millions)
|
Contingent Consideration Obligation
|
||
Balance at June 30, 2015
|
$
|
53
|
|
Additions from acquisitions
|
7
|
|
|
Changes in fair value of contingent consideration (1)
|
(14
|
)
|
|
Payment of contingent consideration
|
(23
|
)
|
|
Balance at December 31, 2015
|
$
|
23
|
|
(1)
|
Amount is included in amortization and other acquisition-related costs in the condensed consolidated statements of earnings.
|
23
|
Cardinal Health
|
Q2 Fiscal 2016 Form 10-Q
|
|
Notes to Financial Statements
|
|
|
(in millions)
|
December 31, 2015
|
|
June 30,
2015 |
||||
Estimated fair value
|
$
|
5,625
|
|
|
$
|
5,521
|
|
Carrying amount
|
5,525
|
|
|
5,492
|
|
(in millions)
|
|
||
Balance at June 30, 2015
|
$
|
—
|
|
Redeemable noncontrolling interests acquired
|
119
|
|
|
Net earnings attributable to redeemable noncontrolling interests
|
1
|
|
|
Balance at December 31, 2015
|
$
|
120
|
|
(in millions)
|
Foreign
Currency
Translation
Adjustments
|
|
Unrealized
Gain/(Loss) on
Derivatives,
net of tax
|
|
Accumulated Other
Comprehensive
Loss
|
||||||
Balance at June 30, 2015
|
$
|
(41
|
)
|
|
$
|
18
|
|
|
$
|
(23
|
)
|
|
|
|
|
|
|
||||||
Other comprehensive loss, net of tax before reclassifications
|
(73
|
)
|
|
(1
|
)
|
|
(74
|
)
|
|||
Amounts reclassified to earnings
|
—
|
|
|
—
|
|
|
—
|
|
|||
Total other comprehensive loss
|
(73
|
)
|
|
(1
|
)
|
|
(74
|
)
|
|||
|
|
|
|
|
|
||||||
Balance at December 31, 2015
|
$
|
(114
|
)
|
|
$
|
17
|
|
|
$
|
(97
|
)
|
|
Three Months Ended December 31
|
||||
(in millions)
|
2015
|
|
2014
|
||
Weighted-average common shares–basic
|
329
|
|
|
331
|
|
|
|
|
|
||
Effect of dilutive securities:
|
|
|
|
||
Employee stock options, restricted share units, and performance share units
|
3
|
|
|
3
|
|
Weighted-average common shares–diluted
|
332
|
|
|
334
|
|
|
Cardinal Health
|
Q2
Fiscal 2016 Form 10-Q
|
24
|
Notes to Financial Statements
|
|
|
|
Six Months Ended December 31
|
||||
(in millions)
|
2015
|
|
2014
|
||
Weighted-average common shares–basic
|
329
|
|
|
333
|
|
|
|
|
|
||
Effect of dilutive securities:
|
|
|
|
||
Employee stock options, restricted share units, and performance share units
|
3
|
|
|
4
|
|
Weighted-average common shares–diluted
|
332
|
|
|
337
|
|
|
Three Months Ended December 31
|
||||||
(in millions)
|
2015
|
|
2014
|
||||
Pharmaceutical
|
$
|
28,287
|
|
|
$
|
22,627
|
|
Medical
|
3,162
|
|
|
2,914
|
|
||
Total segment revenue
|
31,449
|
|
|
25,541
|
|
||
Corporate (1)
|
(4
|
)
|
|
(4
|
)
|
||
Total revenue
|
$
|
31,445
|
|
|
$
|
25,537
|
|
|
Six Months Ended December 31
|
||||||
(in millions)
|
2015
|
|
2014
|
||||
Pharmaceutical
|
$
|
53,427
|
|
|
$
|
43,836
|
|
Medical
|
6,081
|
|
|
5,766
|
|
||
Total segment revenue
|
59,508
|
|
|
49,602
|
|
||
Corporate (1)
|
(9
|
)
|
|
5
|
|
||
Total revenue
|
$
|
59,499
|
|
|
$
|
49,607
|
|
(1)
|
Corporate revenue consists of the elimination of inter-segment revenue and other revenue not allocated to the segments.
|
|
Three Months Ended December 31
|
||||||
(in millions)
|
2015
|
|
2014
|
||||
Pharmaceutical
|
$
|
627
|
|
|
$
|
542
|
|
Medical
|
106
|
|
|
115
|
|
||
Total segment profit
|
733
|
|
|
657
|
|
||
Corporate
|
(170
|
)
|
|
(111
|
)
|
||
Total operating earnings
|
$
|
563
|
|
|
$
|
546
|
|
|
Six Months Ended December 31
|
||||||
(in millions)
|
2015
|
|
2014
|
||||
Pharmaceutical
|
$
|
1,285
|
|
|
$
|
992
|
|
Medical
|
207
|
|
|
229
|
|
||
Total segment profit
|
1,492
|
|
|
1,221
|
|
||
Corporate
|
(309
|
)
|
|
(209
|
)
|
||
Total operating earnings
|
$
|
1,183
|
|
|
$
|
1,012
|
|
(in millions)
|
December 31,
2015 |
|
June 30,
2015 |
||||
Pharmaceutical
|
$
|
20,464
|
|
|
$
|
17,385
|
|
Medical
|
9,741
|
|
|
7,095
|
|
||
Corporate
|
3,302
|
|
|
5,662
|
|
||
Total assets
|
$
|
33,507
|
|
|
$
|
30,142
|
|
25
|
Cardinal Health
|
Q2 Fiscal 2016 Form 10-Q
|
|
Notes to Financial Statements
|
|
|
|
Three Months Ended December 31
|
||||||
(in millions)
|
2015
|
|
2014
|
||||
Restricted share unit expense
|
$
|
17
|
|
|
$
|
18
|
|
Employee stock option expense
|
5
|
|
|
5
|
|
||
Performance share unit expense
|
4
|
|
|
5
|
|
||
Total share-based compensation
|
$
|
26
|
|
|
$
|
28
|
|
|
Six Months Ended December 31
|
||||||
(in millions)
|
2015
|
|
2014
|
||||
Restricted share unit expense
|
$
|
35
|
|
|
$
|
34
|
|
Employee stock option expense
|
10
|
|
|
10
|
|
||
Performance share unit expense
|
11
|
|
|
9
|
|
||
Total share-based compensation
|
$
|
56
|
|
|
$
|
53
|
|
(in millions, except per share amounts)
|
Stock
Options
|
|
Weighted-Average
Exercise Price per
Common Share
|
|||
Outstanding at June 30, 2015
|
8
|
|
|
$
|
46.50
|
|
Granted
|
1
|
|
|
84.19
|
|
|
Exercised
|
(1
|
)
|
|
40.31
|
|
|
Canceled and forfeited
|
—
|
|
|
—
|
|
|
Outstanding at December 31, 2015
|
8
|
|
|
$
|
53.45
|
|
Exercisable at December 31, 2015
|
5
|
|
|
$
|
42.05
|
|
(in millions, except per share amounts)
|
December 31, 2015
|
|
June 30, 2015
|
||||
Aggregate intrinsic value of outstanding options at period end
|
$
|
277
|
|
|
$
|
281
|
|
Aggregate intrinsic value of exercisable options at period end
|
233
|
|
|
193
|
|
||
Weighted-average remaining contractual life of outstanding options (in years)
|
7
|
|
|
6
|
|
||
Weighted-average remaining contractual life of exercisable options (in years)
|
5
|
|
|
5
|
|
(in millions, except per share amounts)
|
Restricted Share Units
|
|
Weighted-Average
Grant Date Fair
Value per Share
|
|||
Nonvested at June 30, 2015
|
3
|
|
|
$
|
59.69
|
|
Granted
|
1
|
|
|
84.22
|
|
|
Vested
|
(1
|
)
|
|
53.96
|
|
|
Canceled and forfeited
|
—
|
|
|
—
|
|
|
Nonvested at December 31, 2015
|
3
|
|
|
$
|
70.84
|
|
|
Cardinal Health
|
Q2
Fiscal 2016 Form 10-Q
|
26
|
Notes to Financial Statements
|
|
|
(in millions, except per share amounts)
|
Performance
Share Units
|
|
Weighted-Average
Grant Date Fair
Value per Share
|
|||
Nonvested at June 30, 2015
|
0.9
|
|
|
$
|
50.31
|
|
Granted
|
0.3
|
|
|
84.26
|
|
|
Vested (1)
|
(0.4
|
)
|
|
39.81
|
|
|
Canceled and forfeited
|
—
|
|
|
—
|
|
|
Nonvested at December 31, 2015
|
0.8
|
|
|
$
|
62.61
|
|
27
|
Cardinal Health
|
Q2 Fiscal 2016 Form 10-Q
|
|
Form 10-Q Cross Reference Index
|
|
|
Item Number
|
|
Page
|
|
|
|
|
Part I. Financial Information
|
|
Item 1
|
||
Item 2
|
||
Item 3
|
||
Item 4
|
||
|
|
|
|
Part II. Other Information
|
|
Item 1
|
||
Item 1A
|
||
Item 2
|
||
Item 3
|
Defaults Upon Senior Securities
|
N/A
|
Item 4
|
Mine Safety Disclosures
|
N/A
|
Item 5
|
Other Information
|
N/A
|
Item 6
|
||
|
||
|
|
|
N/A
|
Not applicable
|
|
|
Cardinal Health
|
Q2
Fiscal 2016 Form 10-Q
|
28
|
Signatures
|
|
|
|
|
Cardinal Health, Inc.
|
|
|
|
Date:
|
February 2, 2016
|
/s/ GEORGE S. BARRETT
|
|
|
George S. Barrett
|
|
|
Chairman and Chief Executive Officer
|
|
|
|
|
|
/s/ MICHAEL C. KAUFMANN
|
|
|
Michael C. Kaufmann
|
|
|
Chief Financial Officer
|
29
|
Cardinal Health
|
Q2 Fiscal 2016 Form 10-Q
|
|
|
|
Page
|
|
ARTICLE I
|
DEFINITIONS AND GENERAL PROVISIONS
|
1
|
|
ARTICLE II
|
ELIGIBILITY AND PARTICIPATION
|
6
|
|
ARTICLE III
|
DEFERRED COMPENSATION AND MATCHING CREDITS
|
7
|
|
ARTICLE IV
|
VESTING
|
11
|
|
ARTICLE V
|
DISTRIBUTION OF BENEFITS
|
12
|
|
ARTICLE VI
|
PLAN ADMINISTRATION
|
16
|
|
ARTICLE VII
|
AMENDMENT AND TERMINATION
|
17
|
|
ARTICLE VIII
|
MISCELLANEOUS PROVISIONS
|
18
|
|
|
|
Exhibit 12.1
|
Cardinal Health, Inc. and Subsidiaries
|
|
Fiscal Year Ended June 30
|
|
Six Months Ended December 31, 2015
|
||||||||||||||||||||
(in millions, except ratios)
|
2011
|
|
2012
|
|
2013
|
|
2014
|
|
2015
|
|
|||||||||||||
Earnings before income taxes
|
$
|
1,518.3
|
|
|
$
|
1,698.1
|
|
|
$
|
888.3
|
|
|
$
|
1,798.3
|
|
|
$
|
1,967.3
|
|
|
$
|
1,087.3
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||
Plus fixed charges:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||
Interest expense
|
95.2
|
|
|
92.3
|
|
|
119.2
|
|
|
129.4
|
|
|
137.0
|
|
|
89.3
|
|
||||||
Capitalized interest
|
5.7
|
|
|
6.0
|
|
|
1.7
|
|
|
1.2
|
|
|
1.8
|
|
|
2.1
|
|
||||||
Amortization of debt offering costs
|
1.8
|
|
|
2.8
|
|
|
3.5
|
|
|
3.6
|
|
|
7.6
|
|
|
2.8
|
|
||||||
Interest portion of rent expense
|
7.1
|
|
|
7.8
|
|
|
8.3
|
|
|
9.8
|
|
|
9.6
|
|
|
5.5
|
|
||||||
Fixed charges
|
109.8
|
|
|
108.9
|
|
|
132.7
|
|
|
144.0
|
|
|
156.0
|
|
|
99.7
|
|
||||||
Plus: amortization of capitalized interest
|
5.3
|
|
|
3.2
|
|
|
3.4
|
|
|
2.9
|
|
|
2.4
|
|
|
1.2
|
|
||||||
Less: capitalized interest
|
(5.7
|
)
|
|
(6.0
|
)
|
|
(1.7
|
)
|
|
(1.2
|
)
|
|
(1.8
|
)
|
|
(2.1
|
)
|
||||||
Earnings
|
$
|
1,627.7
|
|
|
$
|
1,804.2
|
|
|
$
|
1,022.7
|
|
|
$
|
1,944.0
|
|
|
$
|
2,123.9
|
|
|
$
|
1,186.1
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||
Ratio of earnings to fixed charges (1)
|
14.8
|
|
|
16.6
|
|
|
7.7
|
|
|
13.5
|
|
|
13.6
|
|
|
11.9
|
|
(1)
|
The ratio of earnings to fixed charges is computed by dividing fixed charges into earnings before income taxes plus fixed charges and capitalized interest. Fixed charges include interest expense, amortization of debt offering costs and the portion of rent expense that is deemed to be representative of the interest factor. Interest expense recorded on tax exposures has been recorded in income tax expense and has therefore been excluded from the calculation.
|
|
|
Exhibit 31.1
|
1.
|
I have reviewed this Form 10-Q of Cardinal Health, Inc.;
|
2.
|
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
|
3.
|
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
|
4.
|
The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
|
(a)
|
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
|
(b)
|
Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
|
(c)
|
Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
|
(d)
|
Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
|
5.
|
The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
|
(a)
|
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
|
(b)
|
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
|
/s/ G
EORGE
S. B
ARRETT
|
|
George S. Barrett
|
|
Chairman and Chief Executive Officer
|
|
|
|
Exhibit 31.2
|
1.
|
I have reviewed this Form 10-Q of Cardinal Health, Inc.;
|
2.
|
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
|
3.
|
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
|
4.
|
The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
|
(a)
|
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
|
(b)
|
Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
|
(c)
|
Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
|
(d)
|
Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
|
5.
|
The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
|
(a)
|
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
|
(b)
|
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
|
/s/ M
ICHAEL
C. K
AUFMANN
|
|
Michael C. Kaufmann
|
|
Chief Financial Officer
|
|
|
|
Exhibit 32.1
|
(1)
|
the Quarterly Report on Form 10-Q for the quarter ended
December 31, 2015
containing the financial statements of the Company (the “Periodic Report”), which this statement accompanies, fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 (15 U.S.C. 78m or 78o(d)); and
|
(2)
|
the information contained in the Periodic Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
|
|
/s/ G
EORGE
S. B
ARRETT
|
|
George S. Barrett
|
|
Chairman and Chief Executive Officer
|
|
/s/ M
ICHAEL
C. K
AUFMANN
|
|
Michael C. Kaufmann
|
|
Chief Financial Officer
|
|
|
Exhibit 99.1
|
•
|
competitive pressures in the markets in which we operate, including pricing pressures;
|
•
|
increasing consolidation in the healthcare industry, which could give the resulting enterprises greater bargaining power and may increase pressure on prices for our products and services;
|
•
|
uncertainties due to government healthcare reform;
|
•
|
changes to the prescription drug reimbursement formula and related reporting requirements for generic pharmaceuticals under Medicaid;
|
•
|
material reductions in purchases, non-renewal or early termination of contracts, or delinquencies or defaults by key customers;
|
•
|
risks associated with the generic pharmaceutical sourcing venture with CVS Health Corporation, including those relating to our ability to realize and maintain the benefits from the sourcing venture;
|
•
|
actions of regulatory bodies and other governmental authorities, including the U.S. Drug Enforcement Administration ("DEA"), the U.S. Food and Drug Administration and other agencies within the U.S. Department of Health and Human Services, including the Centers for Medicare and Medicaid Services, the Office of Inspector General and the Office for Civil Rights, the U.S. Nuclear Regulatory Commission, the U.S. Federal Trade Commission, the U.S. Customs and Border Protection, various state boards of pharmacy, state controlled substance agencies, state health departments, state insurance departments, state Medicaid departments or comparable regulatory bodies or governmental authorities or foreign equivalents that could delay, limit or suspend product development, manufacturing, distribution, importation or sales or result in warning letters, recalls, seizures, injunctions or monetary sanctions;
|
•
|
the possibility of civil fines levied against us (in excess of the reserve we have accrued) by the U.S. Department of Justice for conduct covered by the settlement agreement that we entered into in connection with the DEA's suspension of our Lakeland, Florida distribution center's registration to distribute controlled substances;
|
•
|
the loss of, or default by, one or more key suppliers for which alternative suppliers may not be readily available;
|
•
|
unfavorable changes to the terms of key customer or supplier relationships, or changes in customer mix;
|
•
|
changes in manufacturers' pricing, selling, inventory, distribution or supply policies or practices;
|
•
|
changes in regulatory policies regarding pharmaceutical manufacturer product pricing practices;
|
•
|
changes in hospital buying groups or hospital buying practices;
|
•
|
changes in the frequency or magnitude of brand or generic pharmaceutical price appreciation, restrictions in the amount of inventory available to us, or changes in the timing or frequency of generic launches or the introduction of brand pharmaceuticals;
|
•
|
uncertainties relating to market conditions for pharmaceuticals;
|
•
|
uncertainties relating to demand for our products and services;
|
•
|
changes in distribution or sourcing models for pharmaceutical and medical/surgical products and services, including an increase in direct and limited distribution;
|
•
|
the costs, difficulties and uncertainties related to the integration of acquired businesses, including liabilities relating to the operations or activities of such businesses prior to their acquisition, and uncertainties relating to our ability to achieve the anticipated results from acquisitions;
|
•
|
uncertainties relating to our ability to achieve the anticipated results from the acquisition of The Harvard Drug Group;
|
•
|
risks and uncertainties relating to the acquisition of Cordis, including the ability to achieve the expected synergies and positive impact to operating results and the additional risks the Cordis acquisition will subject us to relating to regulatory matters, legal proceedings, tax laws or positions and global operations, including the effects of local economic environments and currency volatility;
|
•
|
risks arising from certain of our businesses being Medicare-certified suppliers or participating in state Medicaid programs, which business are subject to accreditation and quality standards and other rules and regulations, including applicable billing, payment and record-keeping requirements;
|
•
|
risks arising from certain of our businesses manufacturing or repackaging pharmaceuticals, which businesses are subject to federal and state laws that establish eligibility for reimbursement by federal and state healthcare programs;
|
•
|
risks arising from possible violations of the U.S. Foreign Corrupt Practices Act, Chinese anti-corruption laws and other similar anti-corruption laws in other jurisdictions and U.S. and foreign export control, trade embargo and customs laws;
|
•
|
risks arising from possible violations of healthcare fraud and abuse laws;
|
•
|
risks arising from our collecting, handling and maintaining patient-identifiable healthcare information and other sensitive personal information, which are subject to federal, state and foreign laws that regulate the use and disclosure of such information;
|
•
|
changes in laws or changes in the interpretation or application of laws or regulations, as well as possible failures to comply with applicable laws or regulations, including as a result of possible misinterpretations or misapplications;
|
•
|
our ability to introduce and market new products and our ability to keep pace with advances in technology;
|
•
|
our ability to maintain adequate intellectual property protections;
|
•
|
costs or claims resulting from potential errors or defects in our manufacturing of medical devices or other products or in our compounding, repackaging, information systems or pharmacy management services that may injure persons or damage property or operations, including costs from remediation efforts or recalls;
|
•
|
the results, costs, effects or timing of any commercial disputes, government contract compliance matters, patent infringement claims,
qui tam
actions or other legal proceedings;
|
•
|
disruption or damage to, or failure of, our information or controls systems, including in the event that the Pharmaceutical segment's planned multi-year systems upgrade is not effectively implemented or fails to operate as intended, or a data security breach;
|
•
|
disruptions to the proper functioning of our critical facilities, including our national logistics center;
|
•
|
the costs, effects, timing or success of restructuring programs or plans;
|
•
|
significant charges to earnings if goodwill or intangible assets become impaired;
|
•
|
increased costs for commodities used in the Medical segment including various components, compounds, raw materials or energy such as oil-based resins, cotton, latex and other commodities;
|
•
|
shortages in commodities, components, compounds, raw materials or energy used by our businesses, including supply disruptions of radioisotopes;
|
•
|
the risks of counterfeit products in the supply chain;
|
•
|
risks associated with volatility and disruption to the global capital and credit markets, which may adversely affect our ability to access credit, our cost of credit and the financial soundness of our customers and suppliers;
|
•
|
bankruptcy, insolvency or other credit failure of a customer or supplier that has a substantial amount owed to us;
|
•
|
risks associated with global operations, including the effect of local economic environments, inflation, recession, currency volatility and global competition, in addition to risks associated with compliance with U.S and international laws relating to global operations;
|
•
|
difficulties or delays in the development, production, manufacturing, sourcing and marketing of new or existing products and services, including difficulties or delays associated with obtaining requisite regulatory consents or approvals associated with those activities;
|
•
|
adverse changes in U.S. or foreign tax laws, unfavorable challenges to our tax positions and payments to settle these challenges; and
|
•
|
uncertainties relating to general political, business, industry, regulatory and market conditions;
|
•
|
other factors described in the “Risk Factors” section of the 2015 Form 10-K.
|